Clinical Trial Update: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study comparing preferences for subcutaneous versus intravenous atezolizumab in non-small cell lung cancer has completed, with results posted on 2024-11…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-21